双鹭药业收盘上涨1.02%，滚动市盈率86.04倍，总市值70.89亿元

金融界2025-03-10

3月10日，双鹭药业今日收盘6.9元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的比值）达到86.04倍，总市值70.89亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均41.57倍，行业中值37.39倍，双鹭药业排名第66位。股东方面，截至2024年9月30日，双鹭药业股东户数61868户，较上次减少1924户，户均持股市值35.28万元，户均持股数量2.76万股...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518507218?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-10 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518507218","market":"sh","top_or_hot":-1,"title":"双鹭药业收盘上涨1.02%，滚动市盈率86.04倍，总市值70.89亿元","media":"金融界","content":"<div>\n<p>3月10日，双鹭药业今日收盘6.9元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的比值）达到86.04倍，总市值70.89亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均41.57倍，行业中值37.39倍，双鹭药业排名第66位。股东方面，截至2024年9月30日，双鹭药业股东户数61868户，较上次减少1924户，户均持股市值35.28万元，户均持股数量2.76万股...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/03/10162648625643.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>双鹭药业收盘上涨1.02%，滚动市盈率86.04倍，总市值70.89亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n双鹭药业收盘上涨1.02%，滚动市盈率86.04倍，总市值70.89亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-10 16:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.jrj.com.cn/2025/03/10162648625643.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月10日，双鹭药业今日收盘6.9元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的比值）达到86.04倍，总市值70.89亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均41.57倍，行业中值37.39倍，双鹭药业排名第66位。股东方面，截至2024年9月30日，双鹭药业股东户数61868户，较上次减少1924户，户均持股市值35.28万元，户均持股数量2.76万股...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/03/10162648625643.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://finance.jrj.com.cn/2025/03/10162648625643.shtml","article_id":"2518507218","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518507218","pubTimestamp":1741595198,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"3月10日，双鹭药业今日收盘6.9元，上涨1.02%，滚动市盈率PE达到86.04倍，总市值70.89亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均41.57倍，行业中值37.39倍，双鹭药业排名第66位。股东方面，截至2024年9月30日，双鹭药业股东户数61868户，较上次减少1924户，户均持股市值35.28万元，户均持股数量2.76万股。北京双鹭药业股份有限公司主要专注于基因工程及相关药物的研究开发和生产经营,紧紧围绕疾病谱的变化布局研发和生产。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0188":"融资融券","002038":"双鹭药业","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"Shuanglu Pharmaceutical closed up 1.02%, with a rolling P/E of 86.04 times and a total market value of 7.089 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002038":1},"content_text":"3月10日，双鹭药业今日收盘6.9元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的比值）达到86.04倍，总市值70.89亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均41.57倍，行业中值37.39倍，双鹭药业排名第66位。股东方面，截至2024年9月30日，双鹭药业股东户数61868户，较上次减少1924户，户均持股市值35.28万元，户均持股数量2.76万股。北京双鹭药业股份有限公司主要专注于基因工程及相关药物的研究开发和生产经营,紧紧围绕疾病谱的变化布局研发和生产。主要产品包括重组人粒细胞刺激因子、重组人白介素-2、重组人白介素-11、重组人碱性成纤维细胞生长因子、替莫唑胺、三氧化二砷、来那度胺、复合辅酶、胸腺五肽、依诺肝素钠、氯雷他定分散片、替米沙坦、多西他赛、阿德福韦酯、杏灵滴丸等,涉及肿瘤、肝病、心脑血管、肾病等领域。公司入选国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)和中关村国家自主创新示范区首批“十百千工程”重点培育企业。2010-2011连续两年被评为最具竞争力的医药上市企业前五名,近几年综合实力迅速提升并已成为国内生物制药的骨干企业。最新一期业绩显示，2024年三季报，公司实现营业收入5.41亿元，同比-30.40%；净利润-16735581.13元，同比-105.27%，销售毛利率68.41%。序号股票简称PE(TTM)PE(静)市净率总市值(元)66双鹭药业86.0417.011.2670.89亿行业平均41.5740.557.33174.03亿行业中值37.3933.702.9074.41亿1万泰生物-287.3767.726.80844.98亿2仁度生物-212.54-212.541.6915.68亿3诺思兰德-86.26-86.2611.4138.97亿4诺诚健华-83.55-49.704.61313.74亿5双成药业-65.86-112.8613.2057.27亿6百济神州-61.21-61.2112.613047.33亿7四环生物-50.41-31.195.0323.47亿8近岸蛋白-45.30-45.301.1624.83亿9益方生物-43.67-43.676.18107.27亿10康希诺-40.82-40.823.05154.66亿11艾迪药业-30.90-30.903.7540.14亿","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518507218","isCrawlerRequest":true}